Biotech and Pharmaceuticals Pharmaceuticals

  • Roche's breakthrough therapies

    CNBC's Meg Tirrell and Daniel O'Day, Roche Holdings COO, discuss the latest developments in immunotherapy and treating bladder cancer.

  • GSK announces $350M cancer deal

    GlaxoSmithKline has announced a $350 million deal with U.K. biotech company Adaptimmune which could be a "real shift" in the way cancer is treated, CNBC's Catherine Boyle reports.

  • Immunotherapies hit ASCO

    This year's biggest cancer conference begins tomorrow. CNBC's Meg Tirrell reports why immunotherapy drugs will be a key theme with drug makers at ASCO.

  • A GlaxoSmithKline logo sits on a sign outside the company's headquarters in London.

    GSK has invited private equity firms to consider making offers for a range of its older drugs, three people with direct knowledge of the matter said.

  • GlaxoSmithKline salespeople in China say the company won't reimburse them for bribes they were ordered to pay out of pocket. FT reports.

  • Men with ED may be able to avoid the awkwardness of a doctor's visit by buying Cialis without a prescription, under a new proposal. NYT reports.

  • Over-the-counter Cialis?

    CNBC's Meg Tirrell reports Sanofi and Eli Lilly announced an agreement to pursue regulatory approval of an over-the-counter version of erectile dysfunction drug Cialis.

  • Botox by Allergan

    Canadian drugmaker Valeant Pharmaceuticals International raised the cash component of its offer for Botox-maker Allergan by $10 per share.

  • Valeant raises Allergan bid

    Valeant is upping its offer for Allergan in a proposal that could now be worth more than $50 billion, reports CNBC's Meg Tirrell.

  • GlaxoSmithKline says Britain's Serious Fraud Office (SFO) has opened a formal criminal investigation into its commercial practices.

  • Is Asia's pharma space in for a consolidation?

    Emilia Falcetti, Analyst, Japan Healthcare Equity Research at Cantor Fitzgerald, discusses whether Asian pharmaceuticals will follow their global peers in "ditching the diversification model."

  • Zeroing in on rising drug prices

    CNBC's Meg Tirrell reports on the high cost of drug prices. Ezekial Emanuel, University of Pennsylvania; and Alex Brill, American Enterprise Institute, share their concerns and solutions for the issue.

  • Positive market signals

    Discussing the best stocks and sectors to own right now, with Peter Costa, Empire Executions, and David Darst, Morgan Stanley Wealth Management.

  • Big move for PTC Therapeutics

    PTC Therapeutics skyrockets on a recommendation for approval in Europe for its Duchenne Muscular Dystrophy drug. CNBC's Meg Tirrell provides insight to the disease and treatment options. Shane Kovacs, PTC Therapeutics CFO, looks at the move in the stock.

  • Drug pricing in US versus world

    CNBC's Meg Tirrell reports why drugs in the U.S. versus the rest of the world are priced differently.

  • Ataluren drives PTC Therapeutics

    CNBC's Meg Tirrell reports shares of PTC Therapeutics are surging on a recommendation of the drug "Ataluren" designed to treat Duchenne muscular dystrophy which could be a billion dollar drug.

  • Why Sovaldi is expensive

    CNBC's Meg Tirrell provides insight to why the price of Gilead's hepatitis C Sovaldi appears high.

  • Fighting back on drug prices

    CNBC's Bertha Coombs reports Express Scripts senior vice president and CMO Dr. Steve Miller has rallied a coalition of insurers and health plan providers to play hard ball with drug maker Gilead for a discount on its new hepatitis C drug.

  • High prescription drug prices

    CNBC's Meg Tirrell compares the value versus the price for Gilead's hepatitis C Sovaldi.

  • When drug costs become too cheap

    CNBC biotech and pharmaceutical reporter Meg Tirrell discusses what happens on the flip-side of high health-care costs—when antibiotic costs become too low and stifle development.